Indeed, high tumour expression of SK1 in ER+ breast cancer is correlated with poor patient survival rates and earlier disease recurrence on tamoxifen (Long et al, 2010a and Watson et al, 2010). This evidence concerns the gene SPHK1 and breast cancer.